(CercleFinance.com) – The Nicox ophthalmology laboratory announces its intention to transfer the listing of its shares from the regulated Euronext Paris market to Euronext Growth Paris and, to this end, calls its shareholders to an ordinary general meeting (AGO) for Tuesday February 14th.
“We believe Euronext Growth is more suited to the company, particularly its size, and would allow us to better focus our resources on our business while benefiting from a listing on a strong and growing stock exchange,” says CBO Gavin spencer.
If the shareholders decide favorably on the project, and subject to the agreement of Euronext Paris, the admission on Euronext Growth Paris will take place within a minimum period of two months following the OGM, and within the limit of 12 months following this assembly.